Erasca, Corvus, and BioAge Target $500M+ Offerings Amid Biotech Fundraising Surge
Erasca; Corvus; BioAge; biotech offerings; fundraising; public offering
FDA Issues Draft Guidance on MRD and CR Endpoints for Accelerated Multiple Myeloma Drug Approvals
FDA guidance; multiple myeloma; MRD; complete response; accelerated approval
J&J Brushes Off MFN Impact, Forecasts $100 Billion Revenue Milestone for 2026
J&J; Johnson & Johnson; MFN; Trump drug pricing; 2026 forecast; $100 billion; MedTech; Innovative Medicine
IntraBio’s Levacetylleucine Succeeds in Phase 3 Trial for Ataxia-Telangiectasia, Plans FDA and EMA Approval
IntraBio; levacetylleucine; Ataxia-Telangiectasia; Phase 3; FDA approval; EMA; rare disease
Congressional 2026 Spending Bill Advances PBM Reforms in Medicare Part D
PBM reforms; government funding bill; Medicare Part D; pharmacy contracts; 2026 appropriations
Novo Offloads Cell Therapy Technologies to Aspect After Retreat from the Field
Novo Nordisk; Aspect; cell therapy; type 1 diabetes; stem cell-derived islet cells; hypoimmune technology
Exciva Raises $59M Series B to Fund Phase 2 Trial of Deraphan for Alzheimer’s Agitation
Exciva; Series B; $59M; Alzheimer’s; agitation; Deraphan; Phase 2; neuropsychiatry
Court Rejects HHS Motion to Dismiss Lawsuit Over US Childhood Vaccine Overhaul as Clinician Groups Push Forward
childhood vaccine overhaul; HHS; lawsuit; ACIP; AAP; CDC; RFK Jr.; immunization schedule
Rentschler Biopharma Announces Executive Board Changes and Next Phase of Corporate Strategy
Rentschler Biopharma; Executive Board Changes; Interim CEO; Corporate Strategy; Uwe Buecheler; Benedikt von Braunmuehl; Christiane Bardroff
Angelini Pharma Appoints Sergio Marullo di Condojanni as New CEO
Angelini Pharma; Sergio Marullo di Condojanni; CEO Appointment; Angelini Industries